Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

A major goal for the treatment of opioid use disorder is to reduce or eliminate the use of illicit opioids. Buprenorphine, a µ-opioid receptor partial agonist and kappa opioid receptor antagonist, is now being developed as a monthly, sustained-release formulation (RBP-6000). The objective of this st...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Psychopharmacol
Main Authors: Nasser, Azmi F., Greenwald, Mark K., Vince, Bradley, Fudala, Paul J., Twumasi-Ankrah, Philip, Liu, Yongzhen, Jones, JP, Heidbreder, Christian
格式: Artigo
語言:Inglês
出版: 2016
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5549150/
https://ncbi.nlm.nih.gov/pubmed/26650971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000000434
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍